Full REMAIN-1 pivotal study enrollment anticipated in summer 2025 ...
Eli Lilly said on Tuesday it had sued two mass compounders for selling unapproved products that contain tirzepatide, the main ...
Lexicon Pharmaceuticals, headquartered in The Woodlands, announced it will exclusively license its drug LX9851 to the maker ...
Whether you’re on a weight loss journey of your own or not, you probably haven’t been able to avoid hearing about the sudden ...
But insulin treatment for type 1 diabetes combined with today’s society have caused obesity rates to increase in those patients – and along with that, the use of GLP-1 drugs. GLP-1 drugs mimic the GLP ...
Health on MSN3d
FDA Says Ozempic Is No Longer in Shortage—Does That Mean the End of Cheaper Copycat Versions?Fact checked by Nick Blackmer Compounded versions of semaglutide, the active ingredient in weight loss drugs like Ozempic and ...
Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish ...
Wave Life Sciences Ltd. shares promising updates on AATD & DMD treatments. Click here for my updated look at WVE stock ...
On track for multiple clinical updates through mid-2026, including further progress from two ongoing clinical programs and initiation of ...
With crucial lessons learned from the manufacturing shortages of injectable GLP-1s, experts say securing adequate supply for ...
Golden Globes host Nikki Glaser shared why she supports people using the injectable drug Ozempic for weight loss, and also ...
Glucagon-like peptide-1 agonists, a class of medications known as GLP-1s, have grown in popularity, initially for the treatment of type 2 diabetes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback